Second malignancies in patients with essential thrombocythaemia [1]

British Journal of Haematology

Volumn 116, Issue 4, 2002, Pages 923-

  Randi, M L ^a   Fabris, F ^a   Girolami, A ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Essential thrombocythaemia; Hydroxxyurea; Secondary malignancies

Indexed keywords

ACETYLSALICYLIC ACID; BUSULFAN; CYTOTOXIC AGENT; HYDROXYUREA; PHOSPHORUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SECOND CANCER; SOLID TUMOR; THROMBOCYTHEMIA; THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BUSULFAN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 18344376529     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2002.3346_1.x     Document Type: Letter

References (4)

1. Hydroxyurea in treatment of patients with essential thrombocythemia at high risk of thrombosis: A prospective, randomized trial
2. Second malignancies in patients treated with busulphan and hydroxy-urea: Long-term follow-up of a randomized clinical trial
3. Experience of the Polycythemia Vera Study Group with essential thrombo-cythemia: A final report on diagnostic criteria, survival and leukemic transition by treatment
4. Leukemia and mye-lodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia